Drug Profile

Cyto 111

Alternative Names: B8-BoNT/C1 ad; B8C1ad; Cyto-111

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CytoDel; NYU Grossman School of Medicine
Class Antidotes; Botulinum toxins; Immunoglobulin fragments; Recombinant fusion proteins
Mechanism of Action Botulinum toxin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2025 No recent reports of development identified for preclinical development in Botulism in USA (Parenteral)
07 Jan 2021 CytoDel has Cyto 111 specific patents granted in the European Union and pending in the US and world wide (CytoDel, January 2021)
07 Jan 2021 Preclinical trials in Botulism in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com